Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy and Safety of a Novel Monopolar Radiofrequency Device for Mid and Lower Face Rejuvenation

12 maggio 2026 aggiornato da: Bo Ri Kim, Seoul National University Bundang Hospital

Efficacy and Safety of a Novel Monopolar Radiofrequency Device for Mid and Lower Face Rejuvenation: A Retrospective Pre-Post Comparative Study

The aim of this study is to evaluate the efficacy and safety of mid- and lower-face lifting and contouring treatments using the novel monopolar radiofrequency device, NeoSculpt.

Panoramica dello studio

Stato

Completato

Intervento / Trattamento

Descrizione dettagliata

Aging of the face progresses through complex structural changes, including a decrease in skin elasticity, collagen loss, changes in subcutaneous fat distribution, and relaxation of the superficial musculoaponeurotic system (SMAS). These changes are particularly prominent in the mid and lower face, which has led to the widespread use of non-invasive energy-based lifting and contouring procedures in cosmetic and dermatology clinical practices.

Traditional laser and high-output radiofrequency (RF) based lifting treatments generally deliver brief high-temperature energy (over 70°C) to tissues, inducing protein denaturation and coagulation, followed by collagen remodeling through the wound healing process to achieve long-term effects. Although these treatments can induce relatively rapid clinical changes, side effects such as pain during the procedure, as well as erythema, edema, and blisters, which are associated with thermal damage, have been reported.

To address these limitations, there has been increasing interest in low-temperature-maintaining RF treatments that minimize tissue degeneration while inducing biological responses. In particular, RF stimulation in the range of 43-45°C is known to be a temperature range that does not induce tissue coagulation and is believed to trigger reactions related to cellular metabolic activation and programmed cell death (apoptosis), rather than necrosis-based damage with accompanying acute inflammatory responses. This approach has advantages, including relatively less pain, shorter recovery times, and the possibility of repeated treatments.

Recent studies have also reported that TRPV1 receptors, activated by thermal stimulation above 43°C, may be associated not only with pain transmission but also with the activation of fibroblasts, regulation of collagen and extracellular matrix (ECM) synthesis, and regulation of adipocyte metabolism. Some experimental studies have observed an increase in fibroblast proliferation and ECM production when RF energy was applied to maintain a temperature range of 43-45°C for a certain period. However, this evidence has been largely limited to studies focusing on the skin layer, and there is still limited systematic human research on the clinical efficacy and safety of RF treatments that simultaneously stimulate both the skin and subcutaneous fat layers.

NeoSculpt is a monopolar RF system designed with a multi-channel handpiece structure using different frequencies (1 MHz and 2 MHz) to deliver energy progressively to the dermal-SMAS interface and subcutaneous fat layers. Through a low-temperature-maintaining RF protocol, it is expected to achieve mid- and lower-face lifting and contouring effects. However, objective data regarding the efficacy, safety, and clinical changes associated with the use of this device in actual clinical settings are not yet sufficiently accumulated.

This study aims to evaluate the clinical outcomes of mid- and lower-face lifting and contouring treatments using the NeoSculpt monopolar RF device through a retrospective pre-post comparative analysis utilizing existing clinical records.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

20

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Corea del Sud, 13620
        • Seoul National University Bundang Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study were conducted on patients who have visited Beautism Clear Skin Dermatology Clinic, received at least three sessions of Neosculpt treatment consistently, and are willing to participate in the research.

Descrizione

Inclusion Criteria:

  • Adult patients who have undergone mid- and lower-face lifting and contouring treatments using NeoSculpt RF
  • Cases where pre- and post-treatment evaluation data are available after completing 3 sessions

Exclusion Criteria:

  • Missing key evaluation data
  • Cases where follow-up observations were not conducted after treatment

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
20 patients
This study is an observational, retrospective cohort study. Considering the number of patients available at a single institution and the feasibility of the study, a total of 20 participants were selected. This is considered the minimum number of subjects required to perform the pre-post comparative analysis planned in this study and to assess the clinical trends and safety of mid- and lower-face lifting and contouring treatments. In this study, personally identifiable information (such as name, resident registration number, etc.) will not be collected, and research data will be anonymized and analyzed using a study ID number. All data will be managed by the principal investigator, and use for purposes other than the research is restricted.
This is a retrospective observational study analyzing existing medical records of patients who received NeoSculpt monopolar radiofrequency treatment as part of routine clinical care at a private dermatology clinic. The investigator did not assign or administer any intervention as part of this study. All clinical photographs, 3D photographic assessments, and ultrasound measurements were obtained during routine clinical visits prior to study initiation.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Clinician-Assessed Improvement in Standardized Clinical Photographs
Lasso di tempo: baseline, 1month, 2month, 3month, 6month
Two blinded dermatologists independently evaluate standardized clinical photographs taken before and after treatment. Improvement is rated on a 5-point scale (0 = no improvement, 1 = minimal improvement [1-25%], 2 = moderate improvement [26-50%], 3 = marked improvement [51-75%], 4 = excellent improvement [>75%]). Higher scores indicate greater improvement.
baseline, 1month, 2month, 3month, 6month
Change in Mid- and Lower-Face Volume Measured by 3D Photographic System
Lasso di tempo: Baseline, Month 1, Month 2, Month 3, Month 6
Facial volume in the mid-cheek, jawline, and nasolabial fold regions is measured using a 3D photographic system. Change from baseline is reported in cubic millimeters (mm³).
Baseline, Month 1, Month 2, Month 3, Month 6
Change in Skin Layer Collagen Thickness Measured by Ultrasound
Lasso di tempo: Baseline, Month 1, Month 2, Month 3, Month 6
Collagen thickness of the dermal layer is measured using high-frequency ultrasound imaging. Change from baseline is reported in millimeters (mm).
Baseline, Month 1, Month 2, Month 3, Month 6
Change in SMAS-Adjacent Adipose Tissue Thickness Measured by Ultrasound
Lasso di tempo: Baseline, Month 1, Month 2, Month 3, Month 6
Thickness of adipose tissue adjacent to the superficial musculoaponeurotic system (SMAS) is measured using high-frequency ultrasound imaging. Change from baseline is reported in millimeters (mm).
Baseline, Month 1, Month 2, Month 3, Month 6
Investigator Global Assessment (IGA) Score for Overall Facial Improvement
Lasso di tempo: Baseline, Month 1, Month 2, Month 3, Month 6
Three independent, blinded dermatologists evaluate overall facial improvement using the Investigator Global Assessment (IGA) scale. Scores range from 0 to 4 (0 = no improvement, 1 = minimal improvement [1-25%], 2 = moderate improvement [26-50%], 3 = marked improvement [51-75%], 4 = excellent improvement [>75%]). Higher scores indicate greater improvement. The mean score across three evaluators is reported.
Baseline, Month 1, Month 2, Month 3, Month 6
Incidence of Treatment-Emergent Adverse Events
Lasso di tempo: baseline, 1month, 2month, 3month, 6month
  • Description: The number and percentage of participants experiencing adverse events following treatment, including but not limited to erythema, edema, blistering, and burns. Adverse events are recorded at each follow-up visit and categorized by type and severity.
  • Unit of Measure: Number of participants with adverse events
baseline, 1month, 2month, 3month, 6month
Duration and Resolution of Adverse Events
Lasso di tempo: Month 1, Month 2, Month 3, Month 6

Description: For participants who experience adverse events, the duration (in days) from onset to resolution is recorded. Clinical course and any management performed are documented at each follow-up visit.

Unit of Measure: Days

Month 1, Month 2, Month 3, Month 6

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient-Reported Pain Score During Treatment
Lasso di tempo: Month 1, Month 2, Month 3
Patients rate procedural pain using a numeric rating scale from 0 to 10 (0 = no pain, 10 = worst imaginable pain). Higher scores indicate greater pain intensity.
Month 1, Month 2, Month 3
Patient-Reported Overall Satisfaction Score
Lasso di tempo: Month 1, Month 2, Month 3, Month 6
Patients rate overall satisfaction with treatment outcome using a numeric rating scale from 0 to 10 (0 = completely dissatisfied, 10 = completely satisfied). Higher scores indicate greater satisfaction.
Month 1, Month 2, Month 3, Month 6

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2025

Completamento primario (Effettivo)

31 dicembre 2025

Completamento dello studio (Effettivo)

31 dicembre 2025

Date di iscrizione allo studio

Primo inviato

28 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 maggio 2026

Primo Inserito (Effettivo)

15 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 maggio 2026

Ultimo verificato

1 aprile 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NeoSculpt_SNUBH

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Dispositivi medici

Sottoscrivi